RedHill Biopharma (RDHL) to Voluntarily Delist from Tel-Aviv Stock Exchange
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
RedHill Biopharma (RDHL) Tops Q3 EPS by 41c
November 19, 2019 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.03, $0.41 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.77 million.
Financial highlights for the quarter ended September 30, 2019:
Net Revenues of $1.4 million in the third quarter of 2019, compared to $1.6 million in the second quarter of 2019. Gross Profit of $0.8 million in the third quarter of 2019, compared to $1.1 million in the second quarter of 2019. Research and Development Expenses of $2.8 million in the third quarter of 2019, compared to $7.0 million in the second quarter of 2019.... More